Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME.
This article continues a series of reports updating recent research developments of particular interest to personnel involved in the treatment and management of patients with heart failure. This is a summary of selected presentations made at the Scientific Sessions of the XXIII Annual Congress of the European Society of Cardiology. Summaries of the following clinical studies are included: WARIS-II, ESCAMI, PAFAC, RITZ-I and TIME.
Coletta
A P
AP
Department of Academic Cardiology, Castle Hill Hospital, Cottingham, HU16 5JQ, Kingston upon Hull, UK.
Cleland
J G
JG
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D004554:Electric Countershock; D005060:Europe; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013450:Sulfones / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D006146:Guanidines; D011725:Pyridines; D013450:Sulfones; D013777:Tetrazoles; D014665:Vasodilator Agents; D014859:Warfarin; C120582:tezosentan; C118397:eniporide; D001241:Aspirin